Bio-Rad Laboratories (BIO-B) Cash from Operations (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Cash from Operations data on file, last reported at 108100000.0 in Q1 2026.

• Cash from Operations for Q1 2026 came in at 108100000.0, down 16.78% year-over-year; the trailing twelve-month figure through Mar 2026 was 510400000.0 (down 0.95% YoY), and the FY2025 annual result was 532200000.0, up 16.92% from the prior year.
• Cash from Operations slipped to 108100000.0 in Q1 2026 per BIO-B's latest filing, from 164900000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 164900000.0 in Q4 2025 and troughed at 10990000.0 in Q3 2022.
• A 5-year average of 97929411.76 and a median of 98066000.0 in 2023 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations tumbled 95.23% in 2022, then surged 789.09% in 2023.
• A 5-year view of Cash from Operations shows it stood at 79610000.0 in 2022, then climbed by 1.75% to 81004000.0 in 2023, then jumped by 53.33% to 124200000.0 in 2024, then surged by 32.77% to 164900000.0 in 2025, then slumped by 34.45% to 108100000.0 in 2026.
• Business Quant data shows BIO-B's Cash from Operations at 108100000.0 in Q1 2026, 164900000.0 in Q4 2025, and 120900000.0 in Q3 2025.